Background/aims To assess epidemiological tumour features, risk factors, clinical management and outcome of eyelid squamous cell carcinoma (SCC) and changes thereof. Furthermore, we searched for validating predictors of the American Joint Committee on Cancer (AJCC) 8 classification system. Methods We evaluated data of 117 patients with histologically proven eyelid SCC at a large tertiary German university centre between January 2009 and March 2020. This retrospective, monocentric analysis included descriptive statistics and non-parametric tests (p<0.05). Results Histologically controlled excision and follow-up was performed in 88 (75.2%) patients. In the remaining patients with higher T-category, individual adjuvant therapy combinations were initiated. We found higher numbers of nodal metastasis and recurrence for male patients and higher T-category (p=0.035, p=0.008 and p=0.001, p<0.001). Recurrence rates proved higher for patients with multiple lesions (p=0.008). Disease-specific survival (DSS) was 95.7% at 2 and 94.9% at 5 years of follow-up. Six patients (5.1%) died from eyelid SCC with nodal metastasis and higher T-category being negative prognostic factors (p<0.001 and p=0.009). Mortality was associated with tumour location in the medial upper eyelid, nodal metastasis being more frequent (p=0.001 and p=0.009) and tumour of the lower eyelid alone as positive predictor (p=0.012). T category differed in 34 (29.1%) patients when comparing AJCC 7 and 8 (p<0.001). Changes in T category as per the AJCC 8 classification resulted in better prediction of DSS (p=0.024). Conclusion Special attention should be paid to male patients, tumour location in the upper medial eyelid and lymph node diagnostics. Prediction of DSS proved superior as per the AJCC 8 staging system. Deidentified participant data are available from the corresponding author upon reasonable request.

中文翻译：

---

2009-2020年某大型三级中心眼睑鳞状细胞癌患者流行病学特征及临床病程

背景/目的 评估眼睑鳞状细胞癌 (SCC) 的流行病学肿瘤特征、危险因素、临床管理和结果及其变化。此外，我们搜索了美国癌症联合委员会 (AJCC) 8 分类系统的验证预测因子。方法 我们评估了 2009 年 1 月至 2020 年 3 月期间在德国一家大型三级大学中心的 117 名经组织学证实的眼睑 SCC 患者的数据。这项回顾性、单中心分析包括描述性统计和非参数检验 (p<0.05)。结果 88 例（75.2%）患者进行了组织学控制的切除和随访。在其余具有较高 T 分类的患者中，开始了单独的辅助治疗组合。我们发现男性患者的淋巴结转移和复发率更高，T 级更高（p=0.035，p=0.008 和 p=0.001，p<0.001）。多处病变患者的复发率更高（p=0.008）。随访 2 年时疾病特异性生存率 (DSS) 为 95.7%，随访 5 年时为 94.9%。6 名患者 (5.1%) 死于眼睑 SCC，伴有淋巴结转移和较高的 T 分类是阴性预后因素 (p<0.001 和 p=0.009)。死亡率与上眼睑内侧的肿瘤位置有关，淋巴结转移更频繁（p=0.001 和 p=0.009），仅下眼睑肿瘤作为阳性预测因子（p=0.012）。比较 AJCC 7 和 8 时，34 名 (29.1%) 患者的 T 类别不同（p<0.001）。根据 AJCC 8 分类，T 类别的变化导致更好地预测 DSS (p=0.024)。结论 应特别注意男性患者、上眼睑肿瘤位置及淋巴结诊断。根据 AJCC 8 分期系统，DSS 的预测被证明是优越的。可根据合理要求从通讯作者处获得身份不明的参与者数据。